LLY Options Signal Bullish Breakout Potential: Target $1200 Calls as Market Digests $1T Milestone

Generated by AI AgentOptions FocusReviewed byAInvest News Editorial Team
Friday, Nov 28, 2025 1:18 pm ET1min read
Aime RobotAime Summary

-

shares fell 2.6% to $1075.20 after hitting $1T market cap, with options data showing heavy call interest at $1200 and defensive puts below $1000.

- Technical indicators suggest a rebound near $1067.80, while Zepbound/Mounjaro's 54% revenue surge and $1.2B Puerto Rico investment justify bullish sentiment.

- Overbought RSI (87.25) and put/call ratio (0.85) highlight short-term volatility risks as traders balance breakout potential against correction threats.

  • LLY trades at $1075.20, down 2.6% from its 52-week high of $1104.34 amid profit-taking after hitting $1 trillion market cap.
  • Options data shows heavy call open interest at $1200 (2302 contracts) and defensive put positioning at $1000–$1030 (1188–1183 OI for next Friday).
  • Technical indicators suggest a rebound near $1067.80 (intraday low) with Bollinger Bands hinting at a $1146.39 upper-bound target.

Here’s the core insight: LLY’s options market is pricing in a bullish breakout above $1200 despite today’s pullback. The stock’s 54% revenue surge from Zepbound/Mounjaro and $1.2B Puerto Rico investment justify this optimism—but traders need to watch for short-term volatility as the market digests these gains.

Bullish Pressure at $1200, Defensive Bets Below $1000

The options chain tells a clear story. For this Friday’s expiration,

(2302 OI) is the most watched strike, with 1280 OI at $1120 and 948 OI at $1100 trailing behind. This suggests big money expects a rebound above $1200 before the close. Meanwhile, next Friday’s put-heavy positioning— (1188 OI) and (1183 OI)—shows hedgers are bracing for a potential dip to $1000. The put/call ratio of 0.85 (favoring calls) reinforces the bullish bias, but don’t ignore the risk: RSI at 87.25 warns of overbought conditions.

News Flow Fuels the Bull Case

Eli Lilly’s recent headlines are a goldmine for bulls. The $1 trillion market cap milestone, Q3 revenue surge, and FDA approval of Omvoh for ulcerative colitis all validate its dominance in metabolic and specialty therapies. Investors are betting on the pipeline—orforglipron’s oral GLP-1 launch in 2026 alone could justify a $1500 price tag. But here’s the catch: the stock’s 49% six-month gain means corrections are inevitable. Today’s 2.6% drop is a reminder that even the strongest narratives need breathing room.

Trade Ideas: Calls for Breakouts, Stock for Rebounds

For options traders, the most compelling setup is LLY20251128C1200 (this Friday’s $1200 call). If the stock rebounds from its intraday low of $1067.80 and closes above $1180 by Friday, this strike could see explosive gains. For a longer-term play,

(next Friday) offers leverage if Lilly’s AI-driven drug discovery with NVIDIA sparks a rally.

Stock buyers should consider entry near $1067.80 (intraday low) with a stop below $1050. A successful rebound would target $1100 (middle Bollinger Band) first, then $1146.39 (upper band). For downside protection, LLY20251205P1000 offers a floor if the stock slips below $1075.20.

Volatility on the Horizon

The next 10 days will test Lilly’s momentum. A close above $1200 would validate the bullish thesis and open the door to $1500+ territory. But if the stock fails to hold $1050, the put-heavy positioning at $1000 could trigger a sharper correction. Either way, the options market has already priced in a high-stakes game of breakout or breakdown—just make sure your strategy matches the direction you’re betting on.

Comments



Add a public comment...
No comments

No comments yet